Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — J.P. Morgan Healthcare Conference 2021
21 slides from Bristol-myers Squibb's conference presentation, Jan 11, 2021
Slide 1: J.P. Morgan Healthcare Conference January 11, 2021
J.P. Morgan Healthcare Conference January 11, 2021
Slide 2: Forward Looking Statement and Non-GAAP Financial Information
Forward Looking Statement and Non-GAAP Financial Information * This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual
Slide 3: A differentiated biopharma company focused on innovative medicines for cancer and other serious diseases
A differentiated biopharma company focused on innovative medicines for patients with cancer and other serious diseases BEST OF BIOTECHBEST OF PHARMA Leading scientific innovationCollaborating at center of the biotech ecosystemLeveraging global scale and agilityDriven by the best people * Our strateg
Slide 4: Strength of execution in 2020 provides foundation for future growth
Strength of execution in 2020 provides foundation for future growth * Successful integration and synergy capture Strong, high-performance organization Commercial launch execution Reblozyl ● Zeposia MS ● Onureg Superior pipeline execution Foundation in place for portfolio renewal Future growth potent
Slide 5: A leading patient-focused biopharmaceutical company
A leading patient-focused biopharmaceutical company * Leading Products across Four Therapeutic Areas Robust Early-stage Pipeline* Across leading drug discovery platforms:Small moleculesProtein homeostasisBiologicsCell & gene therapy Deep and BroadLate-stage Pipeline 8 *Phase I / II Assets Recent/pot
Slide 6: Objectives for growth and portfolio renewal
Objectives for growth and portfolio renewal Deliver top and bottom line growth through 2025 Diversified, earlier life-cycle growth products Strong operating margins & cash generation Grow the business Renew the portfolio Financial strength & flexibility Maximizing our in-line business and launch por
Slide 7: Growing our business from 2020-2025
Bristol Myers Squibb view broadly aligned Expect low to mid-single digit revenue CAGR,* as inline growth products and launches more than offset LOEsStronger conviction on launch product potentialLow double-digit revenue CAGRex-Revlimid & Pomalyst* Maintain strong profitability;low to mid 40s operati
Slide 8: A strong base for continued portfolio renewal in 2025
A strong base for continued portfolio renewal in 2025 * Strong profitability Growth opportunities for new launches through expansion into new indications New launches & registrational opportunities from mid & late-stage pipeline Continued investment in BD LOE products = Revlimid, Pomalyst, Sprycel,
Slide 9: Growth opportunities for the second half of the decade
Growth opportunities for the second half of the decade $20B-$25B in NRA revenue potential* in 2029 Additional potential indications launching in 2025+ Launch portfolio growth potential Mid to late-stage pipeline yields new launch opportunities iberdomide CC-92480 FXIa inhib bempeg Relatlimab Cendaki
Slide 10: Launch portfolio with $20B-$25B revenue replacement power
Deucravacitinib (TYK2i) Psoriasis: 1st Ph3 psoriasis data in-house w/ 2nd Ph3 read-out expected in Q1’21 Ph3 PsA to initiate this yearPh2s ongoing in IBD and lupus, 1st expected 2H21 Launched in TD beta-thal & post-ESA RS+ MDS Ph3 ESA-naïve MDS (COMMANDS) expected 2022+Ph3 MF to initiate this year M
Slide 11: Deucravacitinib (TYK-2i): Potential broad autoimmune therapy
Deucravacitinib (TYK-2i): Potential broad autoimmune therapy * POETYK-2 Q1'21 Beginning Ph3 in 2021 Ph2 PoC 2H’21 Ph2 PoC 2022 Ph2 PoC 2H’21 Ph2 PoC 2022+ Key expansion opportunities Deucravacitinib has the potential to address a broad spectrum of auto-immune diseases 2029 non risk-adjusted sales po
Slide 12: Reblozyl: Differentiated medicine for anemia
Reblozyl: Differentiated medicine for anemia * Patient #s in thousands** 1L MDS (COMMANDS) P1 Myelofibrosis (INDEPENDENCE) P2 P3 Topline 2022+ Ph3 to begin Q1’21 1 Addt’l MDS with COMMANDS (Incremental to MEDALIST)2 Current MDS indication3 Current Beta thal indication *Peak non-risk adjusted revenue
Slide 13: Mavacamten: Expanding our CV franchise
Mavacamten: Expanding our CV franchise Obstructive HCMSignificant unmet need for patients with symptomatic obstructive HCMCurrent options limited to treatment of symptoms e.g. use of beta blockers or highly invasive proceduresA potential first-in-class medicine to potentially address the underlying
Slide 14: Factor XIa inhibitor: Potential to expand antithrombotic therapy
Factor XIa inhibitor: Potential to expand antithrombotic therapy and further renew our CV franchise * Key upcoming Ph2 Proof-of-Concept readouts FXIa-i vs enoxaparinExpected 2021 FXIa-i + clopidogrel + aspirin vs. clopidogrel + aspirin Expected 2022 P1 P2 Total knee replacement (VTE) Secondary strok
Slide 15: CELMoD agents: Unique opportunity to sustain leadership in multiple myeloma
CELMoD agents: Unique opportunity to sustain a leadership position in multiple myeloma Potential to displace IMiD* agents as new foundation Unlock the potential of BCMA targeting Redefine SoC across lines of therapy BCMA Targeting Agents CELMoD agents Combinations Unique potential to create novel co
Slide 16: Well positioned for long-term innovation
Well positioned for long-term innovation Protein Homeostasis * Cell Therapy Immuno-oncology Human Genetics Broad network of external partnerships Opportunity to be industry leaders across key scientific platforms Robust and diverse early pipeline Oncology21 Phase I / II assets Immunology10 Phase I /
Slide 17: Significant financial flexibility to support a balanced approach to capital allocation
Significant financial flexibility to support a balanced approach to capital allocation * ~$22B* cash on-hand as of Q3 2020 *Cash includes cash, cash equivalents and marketable securities; 75% of total cash is in the U.S.**Future dividend payouts illustrated using 2020 dividend rate and requires boar
Slide 18: Significant capacity for business development
Significant capacity for business development Consistent criteria for sourcing external innovation:Focused on therapeutic areas of interest Oncology ● Hematology ● Immunology ● Cardiovascular ● Neurology Business Development is a top priority * Further strengthen the company’s growth profile andsupp
Slide 19: Expected 2021 pipeline milestones
Opdivo (+/- Yervoy) U.S./EU expected approvals:1L RCC (9ER), 1L GC (649, O+Chemo), adj Eso (577), adj MIBC (274) 1L Esophageal (CM-648) Opdivo return to annual growth Relatlimab 1L Melanoma w/ Opdivo Ph3 liso-cel 3L+ DLBCL U.S./EU approval 2L TE and TNE DLBCL 3L+ CLL ide-cel 4L+ MM U.S./EU approval
Slide 20: Established a strong foundation in 2020
Established a strong foundation in 2020Leading in-line medicines, significant short term launch opportunities,and a rich pipeline in each therapeutic area of focusExpect to deliver low to mid-single digit revenue CAGR from 2020 to 2025Strong profitability and financial flexibility enables continued
Slide 21: Bristol Myers Squibb
(lh Bristol Myers Squibb’
Bristol Myers Squibb — J.P. Morgan Healthcare Conference 2021 on 6ix